Treatment News : Novel Vaginal HIV Microbicide Ring Enters Large-Scale Clinical Trial - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 8, 2012

Novel Vaginal HIV Microbicide Ring Enters Large-Scale Clinical Trial

by Tim Horn

AIDS 2012A new clinical trial of a novel drug-infused vaginal microbicide ring to prevent male-to-female transmission of HIV has opened in 17 clinical trials sites in five African countries, according to a National Institutes of Health news announcement and additional details discussed during a press conference at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.

Microbicide Trials Network study 020 (MTN 020)—also known as "A Study to Prevention Infection with a Ring for Extended Use" (ASPIRE)—hopes to enroll nearly 3,500 HIV-negative women at risk for the infection. Results are expected in early 2015.

In July 2010, the CAPRISA 004 clinical trial found that a microbicide gel containing the antiretroviral (ARV) Viread (tenofovir) demonstrated a 39 percent level of efficacy at preventing HIV infection when applied vaginally within 12 hours before and within 12 hours after sex.

In November 2011, however, an interim review of data from another clinical trial—the VOICE study—revealed that the tenofovir gel was no more effective than a placebo gel at preventing HIV infection among females who used the microbicide once daily, regardless of the timing or frequency of sexual acts.

One possible, but unconfirmed, reason for the microbicide’s lackluster results in the VOICE study was poor adherence. Too few women in the trial used the gel as recommended, some experts have suggested.

Enter the ASPIRE study, which will explore a vaginal ring that can give women a discreet, long-acting HIV prevention method they control. This would be particularly helpful in situations where it is difficult or impossible for women to refuse sex, negotiate male condom use with their sexual partners or carefully plan microbicide gel applications.  

The vaginal ring being evaluated in ASPIRE is made of silicone and contains the experimental ARV dapavirine. The drug is continuously released in the vagina and the ring needs to be replaced once every four weeks.

Other vaginal rings in development, according to presenters participating in a scientific session at AIDS 2012, contain the ARVs Invirase (saquinavir), Selzentry (maraviroc) and/or Isentress (raltegravir), with some being combined with hormonal contraceptives.  

The ASPIRE study team, under the direction of Jared Baeten, MD, of the University of Washington in Seattle and Thesla Palanee, PhD, of the Wits Reproductive Health and HIV Institute in Johannesburg, South Africa, will enroll HIV-uninfected women between 18 and 45 years of age in Malawi, South Africa, Uganda, Zambia and Zimbabwe. The participants will be randomly assigned to receive either a silicone ring containing 25 milligrams of dapivirine or a placebo silicone ring. 

During monthly study visits, the women will be tested for HIV and pregnancy and will receive condoms, counseling on how to reduce their risk of becoming infected with HIV and other sexually transmitted infections, and a new silicone ring. Women who become infected with HIV during the study will be told to discontinue using the silicone ring and will be referred to local medical care and support services.

Search: hiv, microbicide, microbicide trials network, mtn, mtn 020, aspire, dapavirine, ring, vaginal, prevention, transmission, women, aids 2012

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:

  comments 1 - 2 (of 2 total)    

Foreverloved619, San Diego, 2012-09-23 00:44:08
I think it's a great , and all but why do these trials always, always take place in Africa first. The answer I come up with is so bad..I really don't want to think that way, but darn....

Keith, , 2012-08-08 17:35:49
as always hope for the best. If it works I would view it as a better choice than drugs. I am dubious about ALL these HIV prevention trials How can you be sure that it the gel or the drug or the vaccine that can and does prevent HIV and not the condoms or just luck

comments 1 - 2 (of 2 total)    

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.